Dry Age-Related Macular Degeneration Market Analysis
A landmark market research report reveals that the global Dry Age-Related Macular Degeneration (AMD) Market is on a robust growth trajectory, projected to nearly double from its 2023 valuation of $12.03 billion to a substantial $22.64 billion by 2031. This forecast reflects a strong Compound Annual Growth Rate (CAGR) of 8.22% over the forecast period 2024-2031.
The dry AMD sector, which focuses on a condition that has long been a challenge in ophthalmology, is experiencing a surge in growth that signals a potential turning point in treatment. This significant expansion is driven by several key factors:
By Stages
By End User
By Age Group
By Diagnosis & Treatment
By Route of Administration
The report underscores that an 8.22% CAGR is particularly notable in this context. Dry AMD has been a "holy grail" in ophthalmology—a prevalent condition lacking effective treatments. This growth rate doesn't just reflect market dynamics; it suggests we're at the brink of a therapeutic revolution in a field long marked by frustration.
Industry players across the spectrum are intensely engaged. Pharmaceutical giants are leveraging their immunology expertise to target inflammation's role in AMD. Biotech firms are pioneering with stem cell-based retinal pigment epithelium (RPE) transplants. Even companies from other sectors are entering—like those using nanotechnology for drug delivery to the back of the eye.
Mental Health Treatment Market
Digital Clinical Trials Market
At present there are zero comments on this article.
Why not be the first to make a comment?
There are zero sub-categories in this parent category.
There are zero sub-categories in this parent category.